Certain Products Containing Tirzepatide and Products Purporting To Contain Tirzepatide; Notice of Request for Submissions on the Public Interest, 101048-101049 [2024-29345]

Download as PDF 101048 Federal Register / Vol. 89, No. 240 / Friday, December 13, 2024 / Notices energy/state-activities/gulf-mexicoactivities. Based on the information provided to BOEM in the unsolicited lease application from Hecate Energy and the response to the RFCI from Invenergy, BOEM finds that both qualified entities have submitted all the information that is required by the Department regulations (30 CFR 585.231); therefore, BOEM finds there is competitive interest in WEA options C and D. As a result of this finding, BOEM will move forward with the competitive lease issuance process following the procedures set forth in 30 CFR 585.210 through 585.226, including holding the next competitive lease sale in the Gulf of Mexico as soon as 2026. Elizabeth Klein, Director, Bureau of Ocean Energy Management. [FR Doc. 2024–29358 Filed 12–12–24; 8:45 am] BILLING CODE 4340–98–P INTERNATIONAL TRADE COMMISSION [Investigation Nos. 701–TA–742–745 and 731–TA–1720–1723 (Preliminary)] Hard Empty Capsules From Brazil, China, India, and Vietnam khammond on DSK9W7S144PROD with NOTICES Determinations On the basis of the record 1 developed in the subject investigations, the United States International Trade Commission (‘‘Commission’’) determines, pursuant to the Tariff Act of 1930 (‘‘the Act’’), that there is a reasonable indication that an industry in the United States is materially injured by reason of imports of hard empty capsules from China, India and Vietnam, and that there is a reasonable indication that an industry in the United States is threatened with material injury by reason of imports of hard empty capsules from Brazil provided for in subheadings 9602.00.10 and 9602.00.50 of the Harmonized Tariff Schedule of the United States, that are alleged to be sold in the United States at less than fair value (‘‘LTFV’’) and imports of the subject merchandise from Brazil, China, India, and Vietnam that are alleged to be subsidized by the governments of Brazil, China, India, and Vietnam.2 1 The record is defined in § 207.2(f) of the Commission’s Rules of Practice and Procedure (19 CFR 207.2(f)). 2 89 FR 91684 and 89 FR 91680, November 20, 2024. VerDate Sep<11>2014 18:12 Dec 12, 2024 Jkt 265001 Commencement of Final Phase Investigations Pursuant to section 207.18 of the Commission’s rules, the Commission also gives notice of the commencement of the final phase of its investigations. The Commission will issue a final phase notice of scheduling, which will be published in the Federal Register as provided in § 207.21 of the Commission’s rules, upon notice from the U.S. Department of Commerce (‘‘Commerce’’) of affirmative preliminary determinations in the investigations under §§ 703(b) or 733(b) of the Act, or, if the preliminary determinations are negative, upon notice of affirmative final determinations in those investigations under §§ 705(a) or 735(a) of the Act. Parties that filed entries of appearance in the preliminary phase of the investigations need not enter a separate appearance for the final phase of the investigations. Any other party may file an entry of appearance for the final phase of the investigations after publication of the final phase notice of scheduling. Industrial users, and, if the merchandise under investigation is sold at the retail level, representative consumer organizations have the right to appear as parties in Commission antidumping and countervailing duty investigations. The Secretary will prepare a public service list containing the names and addresses of all persons, or their representatives, who are parties to the investigations. As provided in section 207.20 of the Commission’s rules, the Director of the Office of Investigations will circulate draft questionnaires for the final phase of the investigations to parties to the investigations, placing copies on the Commission’s Electronic Document Information System (EDIS, https:// edis.usitc.gov), for comment. Background On October 24, 2024, Lonza Greenwood LLC, Greenwood, South Carolina filed petitions with the Commission and Commerce, alleging that an industry in the United States is materially injured or threatened with material injury by reason of subsidized imports of hard empty capsules from Brazil, China, India, and Vietnam and LTFV imports of hard empty capsules from Brazil, China, India, and Vietnam. Accordingly, effective October 24, 2024, the Commission instituted countervailing duty investigation Nos. 701–TA–742–745 and antidumping duty investigation Nos. 731–TA–1720– 1723 (Preliminary). PO 00000 Frm 00100 Fmt 4703 Sfmt 4703 Notice of the institution of the Commission’s investigations and of a public conference to be held in connection therewith was given by posting copies of the notice in the Office of the Secretary, U.S. International Trade Commission, Washington, DC, and by publishing the notice in the Federal Register of October 30, 2024 (89 FR 86370). The Commission conducted its conference on November 14, 2024. All persons who requested the opportunity were permitted to participate. The Commission made these determinations pursuant to §§ 703(a) and 733(a) of the Act (19 U.S.C. 1671b(a) and 1673b(a)). It completed and filed its determinations in these investigations on December 9, 2024. The views of the Commission are contained in USITC Publication 5572 (December 2024), entitled Hard Empty Capsules from Brazil, China, India, and Vietnam: Investigation Nos. 701–TA–742–745 and 731–TA–1720–1723 (Preliminary). By order of the Commission. Issued: December 9, 2024. Lisa Barton, Secretary to the Commission. [FR Doc. 2024–29332 Filed 12–12–24; 8:45 am] BILLING CODE 7020–02–P INTERNATIONAL TRADE COMMISSION [Investigation No. 337–TA–1377] Certain Products Containing Tirzepatide and Products Purporting To Contain Tirzepatide; Notice of Request for Submissions on the Public Interest U.S. International Trade Commission. ACTION: Notice. AGENCY: Notice is hereby given that on December 6, 2024, the presiding administrative law judge (‘‘ALJ’’) issued an Initial Determination Granting-inPart Summary Determination on Violation of Section 337. The ALJ also issued a Preliminary Recommended Determination on Remedy and Bond should a violation be found in the above-captioned investigation. The Commission is soliciting submissions on public interest issues raised by the recommended relief should the Commission find a violation. This notice is soliciting comments from the public and interested government agencies only. FOR FURTHER INFORMATION CONTACT: Ronald A. Traud, Esq., Office of the General Counsel, U.S. International SUMMARY: E:\FR\FM\13DEN1.SGM 13DEN1 khammond on DSK9W7S144PROD with NOTICES Federal Register / Vol. 89, No. 240 / Friday, December 13, 2024 / Notices Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 205–3427. Copies of non-confidential documents filed in connection with this investigation may be viewed on the Commission’s electronic docket (EDIS) at https://edis.usitc.gov. For help accessing EDIS, please email EDIS3Help@usitc.gov. General information concerning the Commission may also be obtained by accessing its internet server at https://www.usitc.gov. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal on (202) 205–1810. SUPPLEMENTARY INFORMATION: Section 337 of the Tariff Act of 1930 provides that, if the Commission finds a violation, it shall exclude the articles concerned from the United States unless, after considering the effect of such exclusion upon the public health and welfare, competitive conditions in the United States economy, the production of like or directly competitive articles in the United States, and United States consumers, it finds that such articles should not be excluded from entry. (19 U.S.C. 1337(d)(1)). A similar provision applies to cease and desist orders. (19 U.S.C. 1337(f)(1)). The Commission is soliciting submissions on public interest issues raised by the recommended relief should the Commission find a violation, specifically: (1) a general exclusion order directed to certain products containing tirzepatide and products purporting to contain tirzepatide imported, sold for importation, and/or sold after importation; (2) in the alternative to a general exclusion order, limited exclusion orders directed to Audrey Beauty Co. of Hong Kong, China; Mew Mews Company Limited of Hong Kong, China; Super Human Store of Barcelona, Spain; Triggered Supplements LLC (d/b/a The Triggered Brand) of Clearwater, Florida (‘‘Triggered Brand’’); Strate Labs LLC of Spring, Texas (‘‘Strate Labs’’); and Xiamen Austronext Trading Co., Ltd. (d/ b/a AustroPeptide) of Fujian, China; and (3) in addition to either a general exclusion order or limited exclusion orders, cease and desist orders directed to Arctic Peptides LLC of Akeny, Iowa; Triggered Brand; and Strate Labs. Parties are to file public interest submissions pursuant to 19 CFR 210.50(a)(4). VerDate Sep<11>2014 18:12 Dec 12, 2024 Jkt 265001 The Commission is interested in further development of the record on the public interest in this investigation. Accordingly, members of the public and interested government agencies are invited to file submissions of no more than five (5) pages, inclusive of attachments, concerning the public interest in light of the ALJ’s Recommended Determination on Remedy and Bonding issued in this investigation on December 6, 2024. Comments should address whether issuance of the recommended remedial orders in this investigation, should the Commission find a violation, would affect the public health and welfare in the United States, competitive conditions in the United States economy, the production of like or directly competitive articles in the United States, or United States consumers. In particular, the Commission is interested in comments that: (i) explain how the articles potentially subject to the recommended remedial orders are used in the United States; (ii) identify any public health, safety, or welfare concerns in the United States relating to the recommended orders; (iii) identify like or directly competitive articles that complainant, its licensees, or third parties make in the United States which could replace the subject articles if they were to be excluded; (iv) indicate whether complainant, complainant’s licensees, and/or thirdparty suppliers have the capacity to replace the volume of articles potentially subject to the recommended orders within a commercially reasonable time; and (v) explain how the recommended orders would impact consumers in the United States. Written submissions must be filed no later than by close of business on January 8, 2025. Persons filing written submissions must file the original document electronically on or before the deadlines stated above. The Commission’s paper filing requirements in 19 CFR 210.4(f) are currently waived. 85 FR 15798 (Mar. 19, 2020). Submissions should refer to the investigation number (‘‘Inv. No. 337–TA–1377’’) in a prominent place on the cover page and/or the first page. (See Handbook for Electronic Filing Procedures, https://www.usitc.gov/ secretary/fed_reg_notices/rules/ handbook_on_electronic_filing.pdf). PO 00000 Frm 00101 Fmt 4703 Sfmt 4703 101049 Persons with questions regarding filing should contact the Secretary (202–205– 2000). Any person desiring to submit a document to the Commission in confidence must request confidential treatment by marking each document with a header indicating that the document contains confidential information. This marking will be deemed to satisfy the request procedure set forth in Rules 201.6(b) and 210.5(e)(2) (19 CFR 201.6(b) & 210.5(e)(2)). Documents for which confidential treatment by the Commission is properly sought will be treated accordingly. Any non-party wishing to submit comments containing confidential information must serve those comments on the parties to the investigation pursuant to the applicable Administrative Protective Order. A redacted non-confidential version of the document must also be filed simultaneously with any confidential filing and must be served in accordance with Commission Rule 210.4(f)(7)(ii)(A) (19 CFR 210.4(f)(7)(ii)(A)). All information, including confidential business information and documents for which confidential treatment is properly sought, submitted to the Commission for purposes of this investigation may be disclosed to and used: (i) by the Commission, its employees and Offices, and contract personnel (a) for developing or maintaining the records of this or a related proceeding, or (b) in internal investigations, audits, reviews, and evaluations relating to the programs, personnel, and operations of the Commission including under 5 U.S.C. Appendix 3; or (ii) by U.S. government employees and contract personnel, solely for cybersecurity purposes. All contract personnel will sign appropriate nondisclosure agreements. All nonconfidential written submissions will be available for public inspection on EDIS. This action is taken under the authority of section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission’s Rules of Practice and Procedure (19 CFR part 210). By order of the Commission. Issued: December 9, 2024. Lisa Barton, Secretary to the Commission. [FR Doc. 2024–29345 Filed 12–12–24; 8:45 am] BILLING CODE 7020–02–P E:\FR\FM\13DEN1.SGM 13DEN1

Agencies

[Federal Register Volume 89, Number 240 (Friday, December 13, 2024)]
[Notices]
[Pages 101048-101049]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-29345]


-----------------------------------------------------------------------

INTERNATIONAL TRADE COMMISSION

[Investigation No. 337-TA-1377]


Certain Products Containing Tirzepatide and Products Purporting 
To Contain Tirzepatide; Notice of Request for Submissions on the Public 
Interest

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that on December 6, 2024, the presiding 
administrative law judge (``ALJ'') issued an Initial Determination 
Granting-in-Part Summary Determination on Violation of Section 337. The 
ALJ also issued a Preliminary Recommended Determination on Remedy and 
Bond should a violation be found in the above-captioned investigation. 
The Commission is soliciting submissions on public interest issues 
raised by the recommended relief should the Commission find a 
violation. This notice is soliciting comments from the public and 
interested government agencies only.

FOR FURTHER INFORMATION CONTACT: Ronald A. Traud, Esq., Office of the 
General Counsel, U.S. International

[[Page 101049]]

Trade Commission, 500 E Street SW, Washington, DC 20436, telephone 
(202) 205-3427. Copies of non-confidential documents filed in 
connection with this investigation may be viewed on the Commission's 
electronic docket (EDIS) at https://edis.usitc.gov. For help accessing 
EDIS, please email [email protected]. General information concerning 
the Commission may also be obtained by accessing its internet server at 
https://www.usitc.gov. Hearing-impaired persons are advised that 
information on this matter can be obtained by contacting the 
Commission's TDD terminal on (202) 205-1810.

SUPPLEMENTARY INFORMATION: Section 337 of the Tariff Act of 1930 
provides that, if the Commission finds a violation, it shall exclude 
the articles concerned from the United States unless, after considering 
the effect of such exclusion upon the public health and welfare, 
competitive conditions in the United States economy, the production of 
like or directly competitive articles in the United States, and United 
States consumers, it finds that such articles should not be excluded 
from entry. (19 U.S.C. 1337(d)(1)). A similar provision applies to 
cease and desist orders. (19 U.S.C. 1337(f)(1)).
    The Commission is soliciting submissions on public interest issues 
raised by the recommended relief should the Commission find a 
violation, specifically: (1) a general exclusion order directed to 
certain products containing tirzepatide and products purporting to 
contain tirzepatide imported, sold for importation, and/or sold after 
importation; (2) in the alternative to a general exclusion order, 
limited exclusion orders directed to Audrey Beauty Co. of Hong Kong, 
China; Mew Mews Company Limited of Hong Kong, China; Super Human Store 
of Barcelona, Spain; Triggered Supplements LLC (d/b/a The Triggered 
Brand) of Clearwater, Florida (``Triggered Brand''); Strate Labs LLC of 
Spring, Texas (``Strate Labs''); and Xiamen Austronext Trading Co., 
Ltd. (d/b/a AustroPeptide) of Fujian, China; and (3) in addition to 
either a general exclusion order or limited exclusion orders, cease and 
desist orders directed to Arctic Peptides LLC of Akeny, Iowa; Triggered 
Brand; and Strate Labs. Parties are to file public interest submissions 
pursuant to 19 CFR 210.50(a)(4).
    The Commission is interested in further development of the record 
on the public interest in this investigation. Accordingly, members of 
the public and interested government agencies are invited to file 
submissions of no more than five (5) pages, inclusive of attachments, 
concerning the public interest in light of the ALJ's Recommended 
Determination on Remedy and Bonding issued in this investigation on 
December 6, 2024. Comments should address whether issuance of the 
recommended remedial orders in this investigation, should the 
Commission find a violation, would affect the public health and welfare 
in the United States, competitive conditions in the United States 
economy, the production of like or directly competitive articles in the 
United States, or United States consumers.
    In particular, the Commission is interested in comments that:
    (i) explain how the articles potentially subject to the recommended 
remedial orders are used in the United States;
    (ii) identify any public health, safety, or welfare concerns in the 
United States relating to the recommended orders;
    (iii) identify like or directly competitive articles that 
complainant, its licensees, or third parties make in the United States 
which could replace the subject articles if they were to be excluded;
    (iv) indicate whether complainant, complainant's licensees, and/or 
third-party suppliers have the capacity to replace the volume of 
articles potentially subject to the recommended orders within a 
commercially reasonable time; and
    (v) explain how the recommended orders would impact consumers in 
the United States.
    Written submissions must be filed no later than by close of 
business on January 8, 2025.
    Persons filing written submissions must file the original document 
electronically on or before the deadlines stated above. The 
Commission's paper filing requirements in 19 CFR 210.4(f) are currently 
waived. 85 FR 15798 (Mar. 19, 2020). Submissions should refer to the 
investigation number (``Inv. No. 337-TA-1377'') in a prominent place on 
the cover page and/or the first page. (See Handbook for Electronic 
Filing Procedures, https://www.usitc.gov/secretary/fed_reg_notices/rules/handbook_on_electronic_filing.pdf). Persons with questions 
regarding filing should contact the Secretary (202-205-2000).
    Any person desiring to submit a document to the Commission in 
confidence must request confidential treatment by marking each document 
with a header indicating that the document contains confidential 
information. This marking will be deemed to satisfy the request 
procedure set forth in Rules 201.6(b) and 210.5(e)(2) (19 CFR 201.6(b) 
& 210.5(e)(2)). Documents for which confidential treatment by the 
Commission is properly sought will be treated accordingly. Any non-
party wishing to submit comments containing confidential information 
must serve those comments on the parties to the investigation pursuant 
to the applicable Administrative Protective Order. A redacted non-
confidential version of the document must also be filed simultaneously 
with any confidential filing and must be served in accordance with 
Commission Rule 210.4(f)(7)(ii)(A) (19 CFR 210.4(f)(7)(ii)(A)). All 
information, including confidential business information and documents 
for which confidential treatment is properly sought, submitted to the 
Commission for purposes of this investigation may be disclosed to and 
used: (i) by the Commission, its employees and Offices, and contract 
personnel (a) for developing or maintaining the records of this or a 
related proceeding, or (b) in internal investigations, audits, reviews, 
and evaluations relating to the programs, personnel, and operations of 
the Commission including under 5 U.S.C. Appendix 3; or (ii) by U.S. 
government employees and contract personnel, solely for cybersecurity 
purposes. All contract personnel will sign appropriate nondisclosure 
agreements. All nonconfidential written submissions will be available 
for public inspection on EDIS.
    This action is taken under the authority of section 337 of the 
Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the 
Commission's Rules of Practice and Procedure (19 CFR part 210).

    By order of the Commission.
    Issued: December 9, 2024.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2024-29345 Filed 12-12-24; 8:45 am]
BILLING CODE 7020-02-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.